Selection of monoclonal antibody E48 IgG or U36 IgG for adjuvant radioimmunotherapy in head and neck cancer patients.

Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that 99mTc-labelled murine monoclonal antibodies (MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In the present study we describe additional aspects of...

Descripción completa

Detalles Bibliográficos
Autores principales: de Bree, R., Roos, J. C., Plaizier, M. A., Quak, J. J., van Kamp, G. J., den Hollander, W., Snow, G. B., van Dongen, G. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1997
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222739/
https://www.ncbi.nlm.nih.gov/pubmed/9083342

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2222739/
https://www.ncbi.nlm.nih.gov/pubmed/9083342

Ejemplares similares